Rune Labs Unveils $12 Million Strategic Round to Accelerate Adoption of Novel Parkinson’s Technologies
Rune Labs , a precision neurology software and data company, today announced a strategic round of $12 million, increasing the total amount raised by the company to over $42 million.
- Rune Labs , a precision neurology software and data company, today announced a strategic round of $12 million, increasing the total amount raised by the company to over $42 million.
- Jordi Parramon, PhD, CEO, General Partner and Co-Founder of Nexus NeuroTech Ventures and former President of Medical Devices at Verily, will join Rune Labs’ board of directors.
- “Focused on investing in technologies that can transform how we treat brain disorders, our aim at Nexus NeuroTech Ventures is to support innovative companies like Rune Labs.
- I strongly believe that Rune Labs and their tool, StrivePD, are set to transform how we receive care and improve outcomes for many people living with Parkinson’s,” said Benjamin Stecher, Chair of the Patient Advisory Board at Rune Labs.